中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

原发性肝癌中医证候判别专家共识及量化工具开发

中国老年学和老年医学学会转化医学分会

引用本文:
Citation:

原发性肝癌中医证候判别专家共识及量化工具开发

DOI: 10.12449/JCH260810
基金项目: 

四大慢病重大专项 (2024ZD0526200);

解放军总医院临床新技术新业务 (2025-YWT-049)

利益冲突声明:本文不存在任何利益冲突。

Expert consensus on traditional Chinese medicine syndrome differentiation and development of quantitative tools for primary liver cancer

Research funding: 

Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0526200);

New Technologies and New Services of Chinese PLA General Hospital (2025-YWT-049)

  • 摘要: 准确的中医辨证是开展中医治疗的重要前提,但目前原发性肝癌的中医证候判别仍缺乏统一标准与可操作的临床应用工具,给临床方案推广及中成药合理使用带来了极大挑战。为统一并规范原发性肝癌的中医证候判别标准,本共识工作组组织中医、中西医结合肝病及方法学领域相关专家开展共同研讨,在系统梳理现有指南、共识及中成药适应证中相关证候描述的基础上,运用两轮德尔菲法开展专家咨询,以均数、变异系数及满分率作为条目筛选标准,构建了涵盖12个证候要素、11个复合证候及其对应诊断条目的证候判别体系,建立了基于条目权重的证候量化模型,并开发了可支持证候积分与症状积分动态录入、实现治疗前后趋势可视化呈现的在线量化工具。本共识系统阐述了上述诊断体系的构建方法与内容,提供了量化、可视化的证候判别及疗效评价工具,旨在为中医辨证的标准化推广提供方法学参考及可操作平台,提升临床辨证一致性与中成药使用的合理性。

     

  • 图  1  原发性肝癌中医证候要素与复合证候分类图

    Figure  1.  Classification diagram of traditional Chinese medicine syndrome elements and composite syndromes in primary liver cancer

    注: GI,证候等级指数。

    图  2  中医证候判别量化实例呈现(假设痰湿证的所有条目均被勾选)

    Figure  2.  Presentation of quantitative examples for traditional Chinese medicine syndrome diagnosis (Assume all items of phlegm-dampness syndrome are selected)

    图  3  症状二维量化示例

    Figure  3.  Two-dimensional quantification examples of symptoms

  • [1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
    [2] National Health Commission of the People’s Republic of China. Guideline for diagnosis and treatment of primary liver cancer(2026 edition)[J]. J Clin Hepatol, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2026年版)[J]. 临床肝胆病杂志, 2026, 42( 4): 794- 827. DOI: 10.12449/JCH260409.
    [3] Zhang Ning, Lu Yinying. Construction of a goal-oriented efficacy evaluation system for traditional Chinese medicine in the prevention and treatment of primary liver cancer[J]. J Clin Hepatol, 2026, 42( 5): 1009- 1014. DOI: 10.12449/JCH260504.

    张宁, 陆荫英. 基于目标导向的原发性肝癌中医药防治疗效评价体系的构建[J]. 临床肝胆病杂志, 2026, 42( 5): 1009- 1014. DOI: 10.12449/JCH260504.
    [4] Branch of Hepatobiliary Diseases, China Association of Chinese Medicine. Guideline for traditional Chinese medicine diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol, 2024, 40( 5): 919- 927. DOI: 10.12449/JCH240509.

    中华中医药学会肝胆病分会. 原发性肝癌中医诊疗指南[J]. 临床肝胆病杂志, 2024, 40( 5): 919- 927. DOI: 10.12449/JCH240509.
    [5] Wu J Y, Tang G Y, Cheng C S, et al. Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: From clinical evidence to drug discovery[J]. Mol Cancer, 2024, 23( 1): 218. DOI: 10.1186/s12943-024-02136-2.
    [6] National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [7] Tian D C, Chen W H, Xu D C, et al. A review of traditional Chinese medicine diagnosis using machine learning: Inspection, auscultation-olfaction, inquiry, and palpation[J]. Comput Biol Med, 2024, 170: 108074. DOI: 10.1016/j.compbiomed.2024.108074.
    [8] Guo P F, Jiang M M, Hu S Q, et al. Advancing the modernization of traditional Chinese medicine through artificial intelligence and multimodal data integration[J]. Chin Med, 2026, 21( 1): 54. DOI: 10.1186/s13020-025-01194-y.
    [9] Shi X Y, He X D, Liu Q, et al. Conducting and reporting the Delphi method in traditional Chinese medicine syndrome diagnosis research: A cross-sectional analysis[J]. Heliyon, 2024, 10( 3): e25162. DOI: 10.1016/j.heliyon.2024.e25162.
    [10] Hasson F, Keeney S, McKenna H. Revisiting the Delphi technique- Research thinking and practice: A discussion paper[J]. Int J Nurs Stud, 2025, 168: 105119. DOI: 10.1016/j.ijnurstu.2025.105119.
    [11] Zhu Wenfeng. Syndrome differentiation[M]. Beijing: People’s Medical Publishing House, 2008.

    朱文锋. 证素辨证学[M]. 北京: 人民卫生出版社, 2008.
    [12] State Administration for Market Regulation, Standardization Administration of China. GB/T 16751.2-2021 Clinic terminology of traditional Chinese medical diagnosis and treatment. Part 2: Syndromes/patterns[S]. Beijing: Standards Press of China, 2021.

    国家市场监督管理总局, 国家标准化管理委员会. GB/T 16751.2-2021 中医临床诊疗术语 第2部分: 证候[S]. 北京: 中国标准出版社, 2021.
    [13] China Anti-Cancer Association Committee of Liver Cancer, Chinese Society of Clinical Oncology, Liver Cancer Group of Chinese Society of Hepatology of Chinese Medical Association. Expert consensus on standardized diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol, 2009, 25( 2): 83- 92. DOI: 10.3969/j.issn.1001-5256.2009.02.001.

    中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治的专家共识[J]. 临床肝胆病杂志, 2009, 25( 2): 83- 92. DOI: 10.3969/j.issn.1001-5256.2009.02.001.
    [14] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol, 2017, 33( 8): 1419- 1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.

    中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33( 8): 1419- 1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
    [15] Ling C Q, Fan J, Lin H S, et al. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine[J]. J Integr Med, 2018, 16( 4): 236- 248. DOI: 10.1016/j.joim.2018.05.002.
    [16] Bureau of Medical Administration, National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol, 2020, 36( 2): 277- 292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36( 2): 277- 292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [17] 2019年肝癌中西医临床协作专家委员会. 原发性肝癌微创消融联合中医诊疗专家共识[J/OL]. 中华介入放射学电子杂志, 2021, 9(1): 9-19. DOI: 10.3877/cma.j.issn.2095-5782.2021.01.002.
    [18] National Science and Technology Major Project of the Ministry of Science and Technology of China- Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis- Research Group of‘Comprehensive Treatment Plan for Retarding Hepatitis B Related Liver Cancer Progression with Traditional Chinese Medicine’, Oncology Expert Committee of Integrated Traditional Chinese and Western Medicine Branch of Chinese Medical Doctor Association, Digestive Rehabilitation Branch of Henan Rehabilitation Medical Association, et al. Expert consensus on integrated traditional Chinese and Western medicine rehabilitation after transcatheter arterial chemoembolization for primary liver cancer[J]. J Clin Hepatol, 2021, 37( 7): 1545- 1549. DOI: 10.3969/j.issn.1001-5256.2021.07.013.

    国家艾滋病和病毒性肝炎等重大传染病防治科技专项“中医药延缓乙型肝炎相关肝癌进展的综合治疗方案研究”课题组, 中国医师协会中西医结合分会肿瘤专业委员会, 河南省康复医学会消化康复分会, 等. 原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识[J]. 临床肝胆病杂志, 2021, 37( 7): 1545- 1549. DOI: 10.3969/j.issn.1001-5256.2021.07.013.
    [19] National Major and Difficult Diseases(Primary Liver Cancer) Clinical Cooperation Group of Traditional Chinese and Western Medicine. Consensus on diagnosis and treatment of primary liver cancer with integrated traditional Chinese and Western medicine[J]. Guid J Tradit Chin Med Pharm, 2021, 27( 9): 101- 107. DOI: 10.13862/j.cnki.cn43-1446/r.2021.09.030.

    国家重大疑难疾病(原发性肝癌)中西医临床协作组. 原发性肝癌中西医结合诊疗专家共识[J]. 中医药导报, 2021, 27( 9): 101- 107. DOI: 10.13862/j.cnki.cn43-1446/r.2021.09.030.
    [20] China Anti-Cancer Association Committee of Liver Cancer. CACA guidelines for holistic integrative management of cancer-liver cancer[J/OL]. J Multidiscip Cancer Manag Electron Version, 2022, 8( 3): 31- 63. DOI: 10.12151/JMCM.2022.03-06.

    中国抗癌协会肝癌专业委员会. 中国肿瘤整合诊治指南(CACA)-肝癌部分[J/OL]. 肿瘤综合治疗电子杂志, 2022, 8( 3): 31- 63. DOI: 10.12151/JMCM.2022.03-06.
    [21] General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [22] 2019年肝癌中西医临床协作专家委员会. 原发性肝癌中西医结合介入诊疗专家共识(试行第一版)[J]. 临床肝胆病杂志, 2022, 38(1): 70-77. DOI: 10.3969/j.issn.1001-5256.2022.01.010.
    [23] Chinese Association of Integrative Medicine, China Association of Chinese Medicine, Chinese Medical Association. Guidelines of diagnosis and treatment of integrated Chinese and Western medicine: Primary liver cancer[S]. Shanghai: Changhai Hospital, 2023.

    中国中西医结合学会, 中华中医药学会, 中华医学会. 原发性肝癌中西医结合诊疗指南[S]. 上海: 长海医院, 2023.
    [24] Branch of Hepatobiliary Diseases, China Association of Chinese Medicine. Guideline for traditional Chinese medicine diagnosis and treatment of primary liver cancer[J]. J Clin Hepatol, 2024, 40( 5): 919- 927. DOI: 10.12449/JCH240509.

    中华中医药学会肝胆病分会. 原发性肝癌中医诊疗指南[J]. 临床肝胆病杂志, 2024, 40( 5): 919- 927. DOI: 10.12449/JCH240509.
    [25] Zheng Xiaoyu. Guiding principles for clinical research of new traditional Chinese medicine(Trial)[M]. Beijing: China Medical Science Press, 2002: 143- 151.

    郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 143- 151.
  • 加载中
图(3)
计量
  • 文章访问数:  15
  • HTML全文浏览量:  10
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2026-06-22
  • 录用日期:  2026-08-06
  • 出版日期:  2026-08-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回